Breaking News, Collaborations & Alliances

AGC Biologics Inks Manufacturing Deal with Faron

The CDMO will manufacture novel precision cancer immunotherapy treatment Clevegen

By: Contract Pharma

Contract Pharma Staff

AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has been selected to commercially manufacture the treatment Clevegen for partner Faron Pharmaceuticals, a clinical stage biopharmaceutical company. Clevegen is a humanized anti-Clever-1 antibody which targets CLEVER-1 positive tumor associated macrophages (TAMs) and converts these highly immunosuppressive M2 macrophages to immune stimulating M1 macrophages. This unique macrophage-directed immuno...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters